Market Overview:
The global human insulin market reached a value of US$ 40.4 Billion in 2021. Looking forward, IMARC Group expects the market to reach US$ 63.5 Billion by 2027, exhibiting a CAGR of 8.6% during 2022-2027. Keeping in mind the uncertainties of COVID-19, we are continuously tracking and evaluating the direct as well as the indirect influence of the pandemic. These insights are included in the report as a major market contributor.
Human insulin (HI) is a form of synthetic insulin that is synthesized in laboratories for pharmaceutical use. It is bio-engineered by growing insulin proteins within E-coli bacteria (Escherichia coli) cells to mimic the properties of insulin naturally present in humans. The HI drugs are available in three kinds, namely rapid-acting, long-acting and premixed. They are used as a solution or suspension and are usually injected subcutaneously and aid in promoting the uptake of glucose from the blood into internal organs, such as fat cells, skeletal muscles and liver. They also inhibit hepatic glucose production, lipolysis and proteolysis and enhance protein synthesis in the body.
The increasing prevalence of obesity and diabetes across the globe is one of the key factors driving the growth of the market. Owing to sedentary lifestyles, growing geriatric population and unhealthy dietary habits, a greater number of individuals are suffering from chronic lifestyle diseases, thereby increasing the demand for insulin therapeutics. Furthermore, the growing requirement for biosimilar drugs, owing to their high efficiency and cost-effectiveness, is providing a boost to the market growth. Various technological advancements, such as the development of pen devices and safety pen needles, to administer HI in the body, are also creating a positive impact on the market growth. In comparison to standard needles, these safety pens ensure minimal injuries, discomfort and infections through bloodborne pathogen transmission. Other factors, including the increasing health consciousness among the masses and extensive research and development (R&D) in the field of biotechnology, are projected to drive the market further.
Key Market Segmentation:
IMARC Group provides an analysis of the key trends in each sub-segment of the global human insulin market, along with forecasts at the global, regional and country level from 2022-2027. Our report has categorized the market based on product type, distribution channel and disease type.
Breakup by Product Type:
- Drugs
- Human Insulin Analogs and Biosimilars
- Rapid Acting
- Long Acting
- Premixed
- Human Insulin Biologics
- Short Acting
- Intermediate Acting
- Premixed
- Delivery Devices
- Pens
- Reusable Pens
- Disposable Pens
- Pen Needles
- Standard Pen Needles
- Safety Pen Needles
- Syringes
- Others
Breakup by Distribution Channel:
- Retail Pharmacies
- Hospital Pharmacies
- Online Retail Stores
- Others
Breakup by Disease Type:
- Type I Diabetes
- Type II Diabetes
Breakup by Region:
- North America
- Asia Pacific
- China
- Japan
- India
- South Korea
- Australia
- Indonesia
- Others
- Europe
- Germany
- France
- United Kingdom
- Italy
- Spain
- Russia
- Others
- Latin America
- Middle East and Africa
Competitive Landscape:
The competitive landscape of the industry has also been examined with some of the key players being B. Braun Melsungen AG, Becton, Dickinson and Company (BD), Biocon, Eli Lilly and Company, Gulf Pharmaceutical Industries (Julphar), Novo Nordisk A/S, Pfizer Inc., Groupe Sanofi, SEDICO Co., Wockhardt Limited, Ypsomed AG, etc.
Report Coverage:
| Report Features |
Details |
|---|
| Base Year of the Analysis |
2021 |
| Historical Period |
2016-2021 |
| Forecast Period |
2022-2027 |
| Units |
US$ Billion |
| Segment Coverage |
Product Type, Distribution Channel, Disease Type, Region |
| Region Covered |
Asia Pacific, Europe, North America, Latin America, Middle East and Africa |
| Countries Covered |
United States, Canada, Germany, France, United Kingdom, Italy, Spain, Russia, China, Japan, India, South Korea, Australia, Indonesia, Brazil, Mexico |
| Companies Covered |
B. Braun Melsungen AG, Becton, Dickinson and Company (BD), Biocon, Eli Lilly and Company, Gulf Pharmaceutical Industries (Julphar), Novo Nordisk A/S, Pfizer Inc., Groupe Sanofi, SEDICO Co., Wockhardt Limited and Ypsomed AG |
| Customization Scope |
10% Free Customization |
| Report Price and Purchase Option |
Single User License: US$ 2499
Five User License: US$ 3499
Corporate License: US$ 4499 |
| Post-Sale Analyst Support |
10-12 Weeks |
| Delivery Format |
PDF and Excel through Email (We can also provide the editable version of the report in PPT/Word format on special request) |
Key Questions Answered in This Report:
- How has the global human insulin market performed so far and how will it perform in the coming years?
- What has been the impact of COVID-19 on the global human insulin market?
- What are the key regional markets?
- What is the breakup of the market based on the product type?
- What is the breakup of the market based on the drug type?
- What is the breakup of the market based on the delivery devices?
- What is the breakup of the market based on the distribution channel?
- What is the breakup of the market based on the disease type?
- What are the various stages in the value chain of the industry?
- What are the key driving factors and challenges in the industry?
- What is the structure of the global human insulin market and who are the key players?
- What is the degree of competition in the industry?
1 Preface
2 Scope and Methodology
2.1 Objectives of the Study
2.2 Stakeholders
2.3 Data Sources
2.3.1 Primary Sources
2.3.2 Secondary Sources
2.4 Market Estimation
2.4.1 Bottom-Up Approach
2.4.2 Top-Down Approach
2.5 Forecasting Methodology
3 Executive Summary
4 Introduction
4.1 Overview
4.2 Key Industry Trends
5 Global Human Insulin Market
5.1 Market Overview
5.2 Market Performance
5.3 Impact of COVID-19
5.4 Market Forecast
6 Market Breakup by Product Type
6.1 Drugs
6.1.1 Market Trends
6.1.2 Market Breakup by Type
6.1.2.1 Human Insulin Analogs and Biosimilars
6.1.2.1.1 Rapid Acting
6.1.2.1.1.1 Market Trends
6.1.2.1.1.2 Market Forecast
6.1.2.1.2 Long Acting
6.1.2.1.2.1 Market Trends
6.1.2.1.2.2 Market Forecast
6.1.2.1.3 Premixed
6.1.2.1.3.1 Market Trends
6.1.2.1.3.2 Market Forecast
6.1.2.2 Human Insulin Biologics
6.1.2.2.1 Short Acting
6.1.2.2.1.1 Market Trends
6.1.2.2.1.2 Market Forecast
6.1.2.2.2 Intermediate Acting
6.1.2.2.2.1 Market Trends
6.1.2.2.2.2 Market Forecast
6.1.2.2.3 Premixed
6.1.2.2.3.1 Market Trends
6.1.2.2.3.2 Market Forecast
6.1.3 Market Forecast
6.2 Delivery Devices
6.2.1 Market Trends
6.2.2 Market Breakup by Type
6.2.2.1 Pens
6.2.2.1.1 Reusable Pens
6.2.2.1.2 Disposable Pens
6.2.2.2 Pen Needles
6.2.2.2.1 Standard Pen Needles
6.2.2.2.2 Safety Pen Needles
6.2.2.3 Syringes
6.2.2.4 Others
6.2.3 Market Forecast
7 Market Breakup by Distribution Channel
7.1 Retail Pharmacies
7.1.1 Market Trends
7.1.2 Market Forecast
7.2 Hospital Pharmacies
7.2.1 Market Trends
7.2.2 Market Forecast
7.3 Online Retail Stores
7.3.1 Market Trends
7.3.2 Market Forecast
7.4 Others
7.4.1 Market Trends
7.4.2 Market Forecast
8 Market Breakup by Disease Type
8.1 Type I Diabetes
8.1.1 Market Trends
8.1.2 Market Forecast
8.2 Type II Diabetes
8.2.1 Market Trends
8.2.2 Market Forecast
9 Market Breakup by Region
9.1 North America
9.1.1 United States
9.1.1.1 Market Trends
9.1.1.2 Market Forecast
9.1.2 Canada
9.1.2.1 Market Trends
9.1.2.2 Market Forecast
9.2 Asia Pacific
9.2.1 China
9.2.1.1 Market Trends
9.2.1.2 Market Forecast
9.2.2 Japan
9.2.2.1 Market Trends
9.2.2.2 Market Forecast
9.2.3 India
9.2.3.1 Market Trends
9.2.3.2 Market Forecast
9.2.4 South Korea
9.2.4.1 Market Trends
9.2.4.2 Market Forecast
9.2.5 Australia
9.2.5.1 Market Trends
9.2.5.2 Market Forecast
9.2.6 Indonesia
9.2.6.1 Market Trends
9.2.6.2 Market Forecast
9.2.7 Others
9.2.7.1 Market Trends
9.2.7.2 Market Forecast
9.3 Europe
9.3.1 Germany
9.3.1.1 Market Trends
9.3.1.2 Market Forecast
9.3.2 France
9.3.2.1 Market Trends
9.3.2.2 Market Forecast
9.3.3 United Kingdom
9.3.3.1 Market Trends
9.3.3.2 Market Forecast
9.3.4 Italy
9.3.4.1 Market Trends
9.3.4.2 Market Forecast
9.3.5 Spain
9.3.5.1 Market Trends
9.3.5.2 Market Forecast
9.3.6 Russia
9.3.6.1 Market Trends
9.3.6.2 Market Forecast
9.3.7 Others
9.3.7.1 Market Trends
9.3.7.2 Market Forecast
9.4 Latin America
9.4.1 Brazil
9.4.1.1 Market Trends
9.4.1.2 Market Forecast
9.4.2 Mexico
9.4.2.1 Market Trends
9.4.2.2 Market Forecast
9.4.3 Others
9.4.3.1 Market Trends
9.4.3.2 Market Forecast
9.5 Middle East and Africa
9.5.1 Market Trends
9.5.2 Market Breakup by Country
9.5.3 Market Forecast
10 SWOT Analysis
10.1 Overview
10.2 Strengths
10.3 Weaknesses
10.4 Opportunities
10.5 Threats
11 Value Chain Analysis
12 Porters Five Forces Analysis
12.1 Overview
12.2 Bargaining Power of Buyers
12.3 Bargaining Power of Suppliers
12.4 Degree of Competition
12.5 Threat of New Entrants
12.6 Threat of Substitutes
13 Price Indicators
14 Competitive Landscape
14.1 Market Structure
14.2 Key Players
14.3 Profiles of Key Players
14.3.1 B. Braun Melsungen AG
14.3.1.1 Company Overview
14.3.1.2 Product Portfolio
14.3.1.3 SWOT Analysis
14.3.2 Becton, Dickinson and Company (BD)
14.3.2.1 Company Overview
14.3.2.2 Product Portfolio
14.3.2.3 Financials
14.3.2.4 SWOT Analysis
14.3.3 Biocon
14.3.3.1 Company Overview
14.3.3.2 Product Portfolio
14.3.3.3 Financials
14.3.3.4 SWOT Analysis
14.3.4 Eli Lilly and Company
14.3.4.1 Company Overview
14.3.4.2 Product Portfolio
14.3.4.3 Financials
14.3.4.4 SWOT Analysis
14.3.5 Gulf Pharmaceutical Industries (Julphar)
14.3.5.1 Company Overview
14.3.5.2 Product Portfolio
14.3.5.3 Financials
14.3.5.4 SWOT Analysis
14.3.6 Novo Nordisk A/S
14.3.6.1 Company Overview
14.3.6.2 Product Portfolio
14.3.6.3 Financials
14.3.6.4 SWOT Analysis
14.3.7 Pfizer Inc.
14.3.7.1 Company Overview
14.3.7.2 Product Portfolio
14.3.7.3 Financials
14.3.7.4 SWOT Analysis
14.3.8 Groupe Sanofi
14.3.8.1 Company Overview
14.3.8.2 Product Portfolio
14.3.8.3 Financials
14.3.8.4 SWOT Analysis
14.3.9 SEDICO Co.
14.3.9.1 Company Overview
14.3.9.2 Product Portfolio
14.3.10 Wockhardt Limited
14.3.10.1 Company Overview
14.3.10.2 Product Portfolio
14.3.10.3 Financials
14.3.11 Ypsomed AG
14.3.11.1 Company Overview
14.3.11.2 Product Portfolio
14.3.11.3 Financials
14.3.11.4 SWOT Analysis
List of Figures
Figure 1: Global: Human Insulin Market: Major Drivers and Challenges
Figure 2: Global: Human Insulin Market: Sales Value (in Billion US$), 2016-2021
Figure 3: Global: Human Insulin Market: Breakup by Product Type (in %), 2021
Figure 4: Global: Human Insulin Drugs Market: Breakup by Type (in %), 2021
Figure 5: Global: Human Insulin Delivery Devices Market: Breakup by Type (in %), 2021
Figure 6: Global: Human Insulin Market: Breakup by Distribution Channel (in %), 2021
Figure 7: Global: Human Insulin Market: Breakup by Disease Type (in %), 2021
Figure 8: Global: Human Insulin Market: Breakup by Region (in %), 2021
Figure 9: Global: Human Insulin Market Forecast: Sales Value (in Billion US$), 2022-2027
Figure 10: Global: Human Insulin (Drugs) Market: Sales Value (in Million US$), 2016 & 2021
Figure 11: Global: Human Insulin Drugs (Analogs and Biosimilars) Market: Sales Value (in Million US$), 2016 & 2021
Figure 12: Global: Human Insulin Drugs (Analogs and Biosimilars- Rapid Acting) Market: Sales Value (in Million US$), 2016 & 2021
Figure 13: Global: Human Insulin Drugs (Analogs and Biosimilars- Rapid Acting) Market Forecast: Sales Value (in Million US$), 2022-2027
Figure 14: Global: Human Insulin Drugs (Analogs and Biosimilars- Long Acting) Market: Sales Value (in Million US$), 2016 & 2021
Figure 15: Global: Human Insulin Drugs (Analogs and Biosimilars- Long Acting) Market Forecast: Sales Value (in Million US$), 2022-2027
Figure 16: Global: Human Insulin Drugs (Analogs and Biosimilars- Premixed) Market: Sales Value (in Million US$), 2016 & 2021
Figure 17: Global: Human Insulin Drugs (Analogs and Biosimilars- Premixed) Market Forecast: Sales Value (in Million US$), 2022-2027
Figure 18: Global: Human Insulin Drugs (Analogs and Biosimilars) Market Forecast: Sales Value (in Million US$), 2022-2027
Figure 19: Global: Human Insulin Drugs (Biologics) Market: Sales Value (in Million US$), 2016 & 2021
Figure 20: Global: Human Insulin Drugs (Biologics - Short Acting) Market: Sales Value (in Million US$), 2016 & 2021
Figure 21: Global: Human Insulin Drugs (Biologics - Short Acting) Market Forecast: Sales Value (in Million US$), 2022-2027
Figure 22: Global: Human Insulin Drugs (Biologics - Intermediate Acting) Market: Sales Value (in Million US$), 2016 & 2021
Figure 23: Global: Human Insulin Drugs (Biologics - Intermediate Acting) Market Forecast: Sales Value (in Million US$), 2022-2027
Figure 24: Global: Human Insulin Drugs (Biologics - Premixed) Market: Sales Value (in Million US$), 2016 & 2021
Figure 25: Global: Human Insulin Drugs (Biologics - Premixed) Market Forecast: Sales Value (in Million US$), 2022-2027
Figure 26: Global: Human Insulin Drugs (Biologics) Market Forecast: Sales Value (in Million US$), 2022-2027
Figure 27: Global: Human Insulin (Drugs) Market Forecast: Sales Value (in Million US$), 2022-2027
Figure 28: Global: Human Insulin (Delivery Devices) Market: Sales Value (in Million US$), 2016 & 2021
Figure 29: Global: Human Insulin Delivery Devices (Pens) Market: Sales Value (in Million US$), 2016 & 2021
Figure 30: Global: Human Insulin Delivery Devices (Pens) Market Forecast: Sales Value (in Million US$), 2022-2027
Figure 31: Global: Human Insulin Delivery Devices (Pen Needles) Market: Sales Value (in Million US$), 2016 & 2021
Figure 32: Global: Human Insulin Delivery Devices (Pen Needles) Market Forecast: Sales Value (in Million US$), 2022-2027
Figure 33: Global: Human Insulin Delivery Devices (Syringes) Market: Sales Value (in Million US$), 2016 & 2021
Figure 34: Global: Human Insulin Delivery Devices (Syringes) Market Forecast: Sales Value (in Million US$), 2022-2027
Figure 35: Global: Human Insulin Delivery Devices (Others) Market: Sales Value (in Million US$), 2016 & 2021
Figure 36: Global: Human Insulin Delivery Devices (Others) Market Forecast: Sales Value (in Million US$), 2022-2027
Figure 37: Global: Human Insulin (Delivery Devices) Market Forecast: Sales Value (in Million US$), 2022-2027
Figure 38: Global: Human Insulin Market: Sales through Retail Pharmacies (in Million US$), 2016 & 2021
Figure 39: Global: Human Insulin Market Forecast: Sales through Retail Pharmacies (in Million US$), 2022-2027
Figure 40: Global: Human Insulin Market: Sales through Hospital Pharmacies (in Million US$), 2016 & 2021
Figure 41: Global: Human Insulin Market Forecast: Sales through Hospital Pharmacies (in Million US$), 2022-2027
Figure 42: Global: Human Insulin Market: Sales through Online Retail Stores (in Million US$), 2016 & 2021
Figure 43: Global: Human Insulin Market Forecast: Sales through Online Retail Stores (in Million US$), 2022-2027
Figure 44: Global: Human Insulin Market: Sales through Other Distribution Channels (in Million US$), 2016 & 2021
Figure 45: Global: Human Insulin Market Forecast: Sales through Other Distribution Channels (in Million US$), 2022-2027
Figure 46: Global: Human Insulin (Type I Diabetes) Market: Sales Value (in Million US$), 2016 & 2021
Figure 47: Global: Human Insulin (Type I Diabetes) Market Forecast: Sales Value (in Million US$), 2022-2027
Figure 48: Global: Human Insulin (Type II Diabetes) Market: Sales Value (in Million US$), 2016 & 2021
Figure 49: Global: Human Insulin (Type II Diabetes) Market Forecast: Sales Value (in Million US$), 2022-2027
Figure 50: North America: Human Insulin Market: Sales Value (in Million US$), 2016 & 2021
Figure 51: North America: Human Insulin Market Forecast: Sales Value (in Million US$), 2022-2027
Figure 52: United States: Human Insulin Market: Sales Value (in Million US$), 2016 & 2021
Figure 53: United States: Human Insulin Market Forecast: Sales Value (in Million US$), 2022-2027
Figure 54: Canada: Human Insulin Market: Sales Value (in Million US$), 2016 & 2021
Figure 55: Canada: Human Insulin Market Forecast: Sales Value (in Million US$), 2022-2027
Figure 56: Asia Pacific: Human Insulin Market: Sales Value (in Million US$), 2016 & 2021
Figure 57: Asia Pacific: Human Insulin Market Forecast: Sales Value (in Million US$), 2022-2027
Figure 58: China: Human Insulin Market: Sales Value (in Million US$), 2016 & 2021
Figure 59: China: Human Insulin Market Forecast: Sales Value (in Million US$), 2022-2027
Figure 60: Japan: Human Insulin Market: Sales Value (in Million US$), 2016 & 2021
Figure 61: Japan: Human Insulin Market Forecast: Sales Value (in Million US$), 2022-2027
Figure 62: India: Human Insulin Market: Sales Value (in Million US$), 2016 & 2021
Figure 63: India: Human Insulin Market Forecast: Sales Value (in Million US$), 2022-2027
Figure 64: South Korea: Human Insulin Market: Sales Value (in Million US$), 2016 & 2021
Figure 65: South Korea: Human Insulin Market Forecast: Sales Value (in Million US$), 2022-2027
Figure 66: Australia: Human Insulin Market: Sales Value (in Million US$), 2016 & 2021
Figure 67: Australia: Human Insulin Market Forecast: Sales Value (in Million US$), 2022-2027
Figure 68: Indonesia: Human Insulin Market: Sales Value (in Million US$), 2016 & 2021
Figure 69: Indonesia: Human Insulin Market Forecast: Sales Value (in Million US$), 2022-2027
Figure 70: Others: Human Insulin Market: Sales Value (in Million US$), 2016 & 2021
Figure 71: Others: Human Insulin Market Forecast: Sales Value (in Million US$), 2022-2027
Figure 72: Europe: Human Insulin Market: Sales Value (in Million US$), 2016 & 2021
Figure 73: Europe: Human Insulin Market Forecast: Sales Value (in Million US$), 2022-2027
Figure 74: Germany: Human Insulin Market: Sales Value (in Million US$), 2016 & 2021
Figure 75: Germany: Human Insulin Market Forecast: Sales Value (in Million US$), 2022-2027
Figure 76: France: Human Insulin Market: Sales Value (in Million US$), 2016 & 2021
Figure 77: France: Human Insulin Market Forecast: Sales Value (in Million US$), 2022-2027
Figure 78: United Kingdom: Human Insulin Market: Sales Value (in Million US$), 2016 & 2021
Figure 79: United Kingdom: Human Insulin Market Forecast: Sales Value (in Million US$), 2022-2027
Figure 80: Italy: Human Insulin Market: Sales Value (in Million US$), 2016 & 2021
Figure 81: Italy: Human Insulin Market Forecast: Sales Value (in Million US$), 2022-2027
Figure 82: Spain: Human Insulin Market: Sales Value (in Million US$), 2016 & 2021
Figure 83: Spain: Human Insulin Market Forecast: Sales Value (in Million US$), 2022-2027
Figure 84: Russia: Human Insulin Market: Sales Value (in Million US$), 2016 & 2021
Figure 85: Russia: Human Insulin Market Forecast: Sales Value (in Million US$), 2022-2027
Figure 86: Others: Human Insulin Market: Sales Value (in Million US$), 2016 & 2021
Figure 87: Others: Human Insulin Market Forecast: Sales Value (in Million US$), 2022-2027
Figure 88: Latin America: Human Insulin Market: Sales Value (in Million US$), 2016 & 2021
Figure 89: Latin America: Human Insulin Market Forecast: Sales Value (in Million US$), 2022-2027
Figure 90: Brazil: Human Insulin Market: Sales Value (in Million US$), 2016 & 2021
Figure 91: Brazil: Human Insulin Market Forecast: Sales Value (in Million US$), 2022-2027
Figure 92: Mexico: Human Insulin Market: Sales Value (in Million US$), 2016 & 2021
Figure 93: Mexico: Human Insulin Market Forecast: Sales Value (in Million US$), 2022-2027
Figure 94: Others: Human Insulin Market: Sales Value (in Million US$), 2016 & 2021
Figure 95: Others: Human Insulin Market Forecast: Sales Value (in Million US$), 2022-2027
Figure 96: Middle East and Africa: Human Insulin Market: Sales Value (in Million US$), 2016 & 2021
Figure 97: Middle East and Africa: Human Insulin Market Forecast: Sales Value (in Million US$), 2022-2027
Figure 98: Global: Human Insulin Industry: SWOT Analysis
Figure 99: Global: Human Insulin Industry: Value Chain Analysis
Figure 100: Global: Human Insulin Industry: Porter’s Five Forces Analysis
List of Tables
Table 1: Global: Human Insulin Market: Key Industry Highlights, 2021 and 2027
Table 2: Global: Human Insulin Market Forecast: Breakup by Product Type (in Million US$), 2022-2027
Table 3: Global: Human Insulin Drugs Market Forecast: Breakup by Type (in Million US$), 2022-2027
Table 4: Global: Human Insulin Delivery Devices Market Forecast: Breakup by Type (in Million US$), 2022-2027
Table 5: Global: Human Insulin Market Forecast: Breakup by Distribution Channel (in Million US$), 2022-2027
Table 6: Global: Human Insulin Market Forecast: Breakup by Disease Type (in Million US$), 2022-2027
Table 7: Global: Human Insulin Market Forecast: Breakup by Region (in Million US$), 2022-2027
Table 8: Global: Human Insulin Market: Competitive Structure
Table 9: Global: Human Insulin Market: Key Players